Infigratinib
Uses- Product Name
- Infigratinib
- CAS No.
- 872511-34-7
- Chemical Name
- Infigratinib
- Synonyms
- BGJ-398;Infligratinib;BGJ;CS-218;BGJ 398;NVP-BGJ398;Infigratinib;Transcrocetinate;NVP-BGJ398, >=98%;BGJ398 (NVP-BGJ398)
- CBNumber
- CB52589643
- Molecular Formula
- C26H31Cl2N7O3
- Formula Weight
- 560.48
- MOL File
- 872511-34-7.mol
Infigratinib Property
- Melting point:
- >211°C (dec.)
- Boiling point:
- 747.9±60.0 °C(Predicted)
- Density
- 1.354
- storage temp.
- -20°C
- solubility
- Soluble in DMSO (up to 5 mg/ml)
- form
- White solid.
- pka
- 11.02±0.70(Predicted)
- color
- White
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
N-Bromosuccinimide Price
- Product number
- 19157
- Product name
- BGJ398
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $62
- Updated
- 2024/03/01
- Product number
- 19157
- Product name
- BGJ398
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $120
- Updated
- 2024/03/01
- Product number
- 19157
- Product name
- BGJ398
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $191
- Updated
- 2024/03/01
- Product number
- 19157
- Product name
- BGJ398
- Purity
- ≥98%
- Packaging
- 25mg
- Price
- $313
- Updated
- 2024/03/01
- Product number
- B367000
- Product name
- BGJ398
- Packaging
- 200mg
- Price
- $425
- Updated
- 2021/12/16
Infigratinib Chemical Properties,Usage,Production
Uses
BGJ 398 is a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
Description
NVP-BGJ398 (872511-34-7) is a potent and selective pan-FGFR inhibitor (IC50?= 0.9nM, 1.4 nM, 1.0 nM, and 60 nM for FGFR1,2,3,4 respectively).1? It has also been used in a mouse model of Achondroplasia (most common form of dwarfism) to correct pathological hallmarks of this condition.
Uses
BGJ 398 is a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
Definition
ChEBI: BGJ-398 is a member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor. It has a role as a fibroblast growth factor receptor antagonist and an antineoplastic agent. It is an aminopyrimidine, a N-arylpiperazine, a N-alkylpiperazine, a dichlorobenzene and a member of phenylureas.
brand name
Truseltiq
General Description
Class: receptor tyrosine kinase; Treatment: cholangiocarcinoma; Other name: NVP-BGJ398; Elimination half-life = 34 h; Protein binding = 96.8%
target
FGFR1
IC 50
FGFR1~4 IC50 = 0.9, 1.4, 1.0, and 60 nM; VEGFR2 IC50 = 180 nM
References
1) Guagnano?et al.?(2011),?Discovery of 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethyl-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)-1-methylurea (NVP-BGJ398),?a Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase?; J. Med. Chem.?54?7066 2) Komla-Ebri?et al.?(2016),?Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model; J. Clin. Invest.?126?1871
Infigratinib Preparation Products And Raw materials
Raw materials
Preparation Products
Infigratinib Suppliers
- Tel
- 44-20819178-90 02081917890
- Fax
- (0)2080432064
- info@novachemistry.com
- Country
- United Kingdom
- ProdList
- 4381
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@carbosynth.com
- Country
- United Kingdom
- ProdList
- 6005
- Advantage
- 58
View Lastest Price from Infigratinib manufacturers
- Product
- Infigratinib (BGJ398) 872511-34-7
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- 98% HPLC
- Supply Ability
- 1kg
- Release date
- 2023-08-02
- Product
- 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea 872511-34-7
- Price
- US $2.00/KG
- Min. Order
- 1g
- Purity
- 98%min
- Supply Ability
- ask
- Release date
- 2020-01-08